Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18956065 | 0.76 | KCNH2 (0.51) | QDPRSLC6A4 | |
| SCHEMBL24782984 | 0.75 | QDPR (0.50) | QDPR | |
| Hydrochloric Acid SCHEMBL18955818 | 0.75 | KCNH2 (0.50) | QDPRSLC6A4 | |
| SCHEMBL8283654 | 0.74 | QDPR (0.56) | QDPR | |
| SCHEMBL31718158 | 0.73 | QDPR (0.63) | QDPR | |
| Hydrochloric Acid SCHEMBL28887623 | 0.73 | QDPR (0.44) | QDPRSLC6A4 | |
| SCHEMBL25742872 | 0.73 | KCNH2 (0.41) | QDPRSLC6A4 | |
| SCHEMBL16118259 | 0.72 | NAMPT (0.52) | — | |
| SCHEMBL8584852 | 0.72 | QDPR (0.50) | QDPRSLC6A4 | |
| SCHEMBL8172220 | 0.72 | QDPR (0.62) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2000037074-A1 | MUTILIN 14-ESTER DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | QDPR 465/4885SLC6A4 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.